TickerTalks
Browse all tickers →
TickerTalks›$VRTX
VRVRTX

Vertex Pharmaceuticals Incorporated

Strong FundamentalsStrong FundamentalsRevenue growing 8% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (839/wk), no spike
$VRTX·$123B·Biotechnology·Healthcare
$485.65-0.1%YTD+6.9%1Y+4.8%
Mentions · last 7 days
2026-07-11: 45 posts2026-07-12: 112 posts2026-07-13: 165 posts2026-07-14: 61 posts2026-07-15: 62 posts2026-07-16: 12 posts2026-07-17: 10 posts479+9%
Price updated 3h ago·X counts updated 3h ago
VRVRTX
$VRTXVertex Pharmaceuticals Incorporated
$485.65-0.08%479 posts+9%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $VRTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-07-16

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

$10B all-cash Crinetics acquisition at 102% premium — Vertex's biggest-ever M&A moves the tape into August 3 earnings.

Vertex Pharmaceuticals is the cystic-fibrosis franchise leader (Trikafta) diversifying into pain (JOURNAVX) and now endocrinology via the Crinetics acquisition. The 2026 tape is +5% YTD with the biggest-ever M&A deal just announced.

  • The core business is executing cleanly: Q1 2026 revenue grew 7.8% YoY to $3.0B, gross margin held at 87%, and operating margin was 38% — this is what a diversified biopharma compounder looks like, and the Trikafta base is what funds the strategic diversification.
  • The Crinetics acquisition is a real strategic pivot: all-cash $85/share (~$8.8B net / $10B equity) at approximately 102% premium, funded via cash, debt, and $4.5B bridge — adding endocrinology (Palsonify) as a new therapeutic area meaningfully reduces Vertex's reliance on cystic fibrosis.
  • The market read is 'Big-Pharma-going-after-TAM' signal: bulls describe this as a real signal for the sector, and the monthly base setup already looks constructive — real institutional conviction into the August 3 print.

The August 3 Q2 earnings are the near-term arbiter — Crinetics acquisition-integration commentary, JOURNAVX pain-therapy revenue trajectory, and any specific Casgevy sickle-cell revenue extend the coiling setup toward $520. A Crinetics-integration timing delay or JOURNAVX pain-launch miss stalls the tape near current levels.

Agrees with X sentimentX is bullish, cites Vertex's largest-ever M&A deal ($85/share all-cash / $10B equity Crinetics acquisition at ~102% premium) as a 'Big-Pharma-going-after-TAM signal,' with the monthly base setup already looking constructive. Mechanics validate: Q1 revenue +7.8% YoY at 87% gross margin and 38% operating margin. The Crinetics deal is a real strategic diversification into endocrinology, and the August 3 print has to affirm the integration timing.

What to watch: The August 3 Q2 earnings. Watch Crinetics acquisition-integration commentary, JOURNAVX pain-therapy revenue trajectory, and Casgevy sickle-cell revenue. Crinetics-integration delay or JOURNAVX pain-launch miss stalls the tape near current levels; steady numbers + Crinetics on-track extends toward $520.

On the calendar: 2026-08-03 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment17 posts analyzed · as of 2026-07-14

Vertex Pharmaceuticals signed its largest-ever M&A deal, an all-cash $85/share (~$8.8B net / $10B equity) acquisition of Crinetics Pharmaceuticals at approximately a 102% premium, funded via cash, debt and a $4.5B bridge and adding endocrinology (Palsonify) as a new therapeutic area, further reducing VRTX's reliance on its cystic-fibrosis business. Bulls describe this as a Big-Pharma-going-after-TAM signal, with the monthly base setup already looking explosive, and Elliott-wave technicians frame the recent ((2)) pullback as intact for a continued rally in the bullish weekly sequence. There is essentially no bear thesis in the sample.

Read the AI verdict + X sentiment for $VRTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Dominates cystic fibrosis treatment with TRIKAFTA; expanding pipeline covers pain (non-opioid VX-548), APOL1 kidney disease, and type 1 diabetes.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $VRTX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $VRTX

Partial — Dominates cystic fibrosis treatment with TRIKAFTA; expanding pipeline covers pain (non-opioid VX-548), APOL1 kidney disease, and type 1 diabetes; this segment overlaps with the GLP-1 pipeline bifurcation and ADA oral formulation competition but is not the dominant revenue driver.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+44.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
31.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
17.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
39.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
10.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
23.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
86.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 4, 2026$4.47$4.24+5.4%
Q4 2025Feb 12, 2026$5.03$5.11-1.6%
Q3 2025Nov 3, 2025$4.80$4.57+5.0%
Q2 2025Aug 4, 2025$4.52$4.29+5.4%
Next earningsMon, Aug 3·consensus EPS $4.73

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.0B+7.8%86.8%38.1%$4.06$1.3B
Q4 FY25$3.2B+10.8%85.6%40.3%$4.69$348.6M
Q3 FY25$3.1B+11.0%86.5%38.6%$4.24$1.1B
Q2 FY25$3.0B+12.1%86.3%38.8%$4.02$927.4M

Forward consensus

5-year forecast · up to 25 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$13.1B$13.0B – $13.2B$19.21$18.75 – $19.6523
FY27$14.3B$13.4B – $16.2B$21.33$19.56 – $23.4822
FY28$15.9B$15.9B – $15.9B$25.00$18.26 – $34.9025
FY29$17.7B$17.1B – $19.0B$28.93$27.61 – $31.7212
FY30$19.6B$18.9B – $21.0B$33.50$31.96 – $36.7212

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.72%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+6.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 253.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.295-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 2Ourania TatsisEVP, Chief Reg. & Quality Off.1.5K sh$787KSellJul 2Duncan MckechnieEVP, Chief Commercial Officer1.5K sh$800KSellJul 1Joy LiuEVP and Chief Legal Officer828 sh$416KSellJun 26Carmen BozicEVP and CMO596 sh$288KSellJun 18Carmen BozicEVP and CMO1.0K sh$471KSellJun 15Carmen BozicEVP and CMO4.1K sh$1.8MSellJun 5Carmen BozicEVP and CMO1.7K sh$785KSellMay 29Carmen BozicEVP and CMO2.0K sh$888KSellMay 15Mark E. BunnageEVP, Chief Scientific Officer33 sh$15KSellMay 15Carmen BozicEVP and CMO1.4K sh$614K
1–10 of 20
+ 16 other (12 awards · 4 returns) in window

See when $VRTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJul 78-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Vertex Pharmaceuticals Incorporated signed an Agreement and Plan of Merger on July 6, 2026 to acquire Crinetics Pharmaceuticals, Inc. in an all-cash deal at $85.00 per share, with Crinetics surviving as a wholly owned Vertex subsidiary. All outstanding unvested equity (options and RSUs) will accelerate and convert to the right to receive $85.00 (less any exercise price for options). Closing is subject to customary conditions. Transformative acquisition for Vertex, adding Crinetics' endocrine/rare disease pipeline to Vertex's portfolio at a significant cash premium — signals Vertex's intent to diversify beyond its core CF franchise.

8-KOfficer or director changeMay 138-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Vertex Pharmaceuticals held its 2026 Annual Meeting on May 13, 2026. Shareholders elected all 10 director nominees (including CEO Reshma Kewalramani, Jeffrey Leiden, Sangeeta Bhatia, and others) and approved the 2026 Stock and Option Plan, which replaces the 2013 plan. The new plan was approved by the Board on March 27, 2026. Vertex's strong governance and shareholder base typically result in routine approval of management proposals; the new equity plan provides incentive compensation capacity under an updated structure.

8-KOfficer or director changeApr 298-K — Item 5.02: Officer or director change
3New insider — initial holdingsMar 33
3New insider — initial holdingsFeb 33
+ 25 other (7 S-8 POSs · 5 13Gs · 3 proxys · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on Itzacks.com·2d agoHere's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticalsfool.com·4d agoVertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investorszacks.com·4d agoDoes Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?fool.com·4d agoVertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhousemarketbeat.com·6d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$AURA$SLS$RXRX
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport